- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06768671
En åpen, enkeltarmsstudie for å evaluere farmakokinetikken og sikkerheten til subkutan sonelokimab hos ungdom med moderat til alvorlig Hidradenitis Suppurativa (VELA-TEEN)
En åpen, enkeltarmsstudie for å evaluere farmakokinetikken og sikkerheten til subkutan sonelokimab hos ungdom i alderen ≥12 til ≤17 år på studietidspunktet inkludering med aktiv moderat til alvorlig Hidradenitis Suppurativa
This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Arkansas
-
North Little Rock, Arkansas, Forente stater, 72117
- Clinical Site
-
-
California
-
Stanford, California, Forente stater, 94304
- Clinical Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Clinical Site
-
-
Florida
-
Hollywood, Florida, Forente stater, 33201
- Clinical Site
-
Miami, Florida, Forente stater, 33136
- Clinical Site
-
-
Georgia
-
Macon, Georgia, Forente stater, 31217
- Clinical Site
-
Sandy Springs, Georgia, Forente stater, 30328
- Clinical Site
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Clinical Site
-
-
Indiana
-
Columbus, Indiana, Forente stater, 47201
- Clinical Site
-
-
Kentucky
-
Murray, Kentucky, Forente stater, 42071
- Clinical Site
-
-
Michigan
-
Waterford, Michigan, Forente stater, 48328
- Clinical Site
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58103
- Clinical Site
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Clinical Site
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Clinical Site
-
Dallas, Texas, Forente stater, 75390-8575
- Clinical Site
-
San Antonio, Texas, Forente stater, 78218
- Clinical Site
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Clinical Site
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Clinical Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants must be between ≥12 and ≤17 years of age at the time of signing the informed consent.
- Participants who are diagnosed with HS as determined by the investigator and have a history of signs and symptoms of HS for ≥6 months before signing the informed consent.
- Participants who have moderate to severe HS as determined by the refined Hurley staging (Stages IB and IC, IIB and IIC, and III).
- Participants who have had an inadequate response to appropriate systemic antibiotics for treatment of HS .
- Participants must be up to date with age-appropriate vaccine requirements 8 weeks prior to entry in the study.
- Participants with a body weight of ≥ 40 kg.
Exclusion Criteria:
- Participants with a known hypersensitivity to sonelokimab or any of its excipients.
- Participants with a draining fistula count of ≥20 at the Screening Visit.
- Participants with any other active skin disease or condition that may, in the opinion of the investigator, interfere with the assessment of HS.
- Participants with underlying conditions that, in the opinion of the investigator, potentially compromise the participant and/or places the participant at unacceptable risk.
- Participants who have history or concurrent clinically significant medical conditions or any other reason, including any physical, psychological, or psychiatric condition, that in the opinion of the investigator would compromise the safety or interfere with participation in the study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk.
- Participants with any other skin disease or other medical condition that in the opinion of the investigator would interfere with an accurate assessment of clinical symptoms of HS.
- Participants with a confirmed or suspected diagnosis of inflammatory bowel disease.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: sonelokimab
Subjects will receive sonelokimab 120mg subcutaneously (SC) as an induction regimen of 4 doses, followed by sonelokimab SC every 4 weeks maintenance dose starting at Week 8 |
Open label |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetics (PK) of sonelokimab in adolescents
Tidsramme: Week 24
|
PK (trough concentrations) of sonelokimab over 24 weeks of treatment |
Week 24
|
|
Adverse events (AEs) following treatment with sonelokimab in adolescents
Tidsramme: Week 24
|
Incidence, relatedness, severity and seriousness of all AEs over 24 weeks of treatment from baseline |
Week 24
|
|
Discontinuation of sonelokimab treatment due to AEs
Tidsramme: Week 24
|
Number of participants discontinued from sonelokimab treatment due to AE over 24 weeks of treatment from baseline |
Week 24
|
|
Clinically significant changes in clinical laboratory parameters
Tidsramme: Week 24
|
Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline |
Week 24
|
|
Clinically significant changes in vital signs
Tidsramme: Week 24
|
Number of participants with clinically significant changes in vital signs from baseline |
Week 24
|
|
Clinically significant changes in standard 12-lead electrocardiogram (ECG) intervals
Tidsramme: Week 24
|
Number of participants with clinically significant changes in 12-lead ECG intervals from baseline |
Week 24
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Hidradenitis Suppurativa Clinical Response (HiSCR)75
Tidsramme: Week 24
|
Percentage of participants achieving a HiSCR75 response over time |
Week 24
|
|
Hidradenitis Suppurativa Clinical Response (HiSCR) 50
Tidsramme: Week 24
|
Percentage of participants achieving a HiSCR50 response over time |
Week 24
|
|
International Hidradenitis Suppurativa Severity Score System (IHS4)
Tidsramme: Week 24
|
Absolute change in IHS4 score over time |
Week 24
|
|
Children's Dermatology Life Quality Index (CDLQI)
Tidsramme: Week 24
|
Percentage of participants achieving a CDLQI total reduction of ≥2.5 over time among participants with a baseline CDLQI ≥2.5 |
Week 24
|
|
Numerical Rating Scale (NRS) 30
Tidsramme: Week 24
|
Percentage of participants achieving a ≥30% reduction and a ≥2-unit reduction over time in the NRS30 for pain in PGA among participants with a baseline NRS ≥3 |
Week 24
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Infeksjoner
- Betennelse
- Bakterielle infeksjoner
- Bakterielle infeksjoner og mykoser
- Hudsykdommer, smittsomme
- Patologiske tilstander, tegn og symptomer
- Hud- og bindevevssykdommer
- Hidradenitis Suppurativa
- Hidradenitt
- Hudsykdommer
- Hudsykdommer, bakteriell
- Svettekjertelsykdommer
- Suppuration
- Sonelokimab
Andre studie-ID-numre
- M1095-HS-304
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .